Retatrutide: the triple-agonist weight loss peptide

If you've been following the weight loss peptide space, you've watched the conversation shift from semaglutide to tirzepatide and now to a compound that may surpass both: retatrutide. Developed by Eli Lilly, retatrutide is a first-in-class triple hormone receptor agonist — a single molecule that activates GLP-1, GIP, and glucagon receptors simultaneously. In its Phase 3 clinical trial, participants lost an average of 28.7% of their body weight. That's the highest figure ever recorded for any obesity medication in a clinical setting.

But record-breaking numbers come with important context. Retatrutide is not FDA-approved. It has not completed its full Phase 3 program. And the addition of glucagon receptor activity — the feature that makes retatrutide unique — introduces both benefits and side effects that earlier GLP-1 medications don't produce. Here's what the research actually tells us, and what it doesn't.

What is retatrutide and how does it work?

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide. To understand why it matters, it helps to see how it fits into the progression of incretin-based weight loss drugs:

• Semaglutide (Wegovy, Ozempic) activates one receptor: GLP-1. It slows gastric emptying, reduces appetite, and improves blood sugar control. Clinical trials showed approximately 15% average weight loss.
• Tirzepatide (Mounjaro, Zepbound) activates two receptors: GLP-1 and GIP. The addition of GIP amplified weight loss to roughly 22.5% and improved insulin sensitivity beyond what semaglutide achieved alone.
• Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon receptor is the new element, and it changes the metabolic equation significantly.

Each receptor does something different. GLP-1 suppresses appetite and slows digestion. GIP enhances insulin secretion and appears to amplify GLP-1's appetite-suppressing effects. Glucagon — the same hormone your body produces to raise blood sugar during fasting — increases energy expenditure, accelerates fat oxidation, and drives liver fat reduction.

That third receptor is what separates retatrutide from everything before it. While semaglutide and tirzepatide primarily reduce calorie intake, retatrutide also increases calorie output. The result is a dual mechanism: you eat less and your body burns more energy at rest.

What does the clinical research show?

Retatrutide has more rigorous clinical data than most research peptides — it's backed by Eli Lilly and has progressed through Phase 2 and into Phase 3 trials. The results so far are striking.

Phase 2 trial (2023)

Published in the New England Journal of Medicine, the Phase 2 trial enrolled 338 adults with obesity or overweight. Participants received weekly injections of retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg for 48 weeks. The results:

• 12 mg dose: 24.2% mean body weight reduction at 48 weeks
• 8 mg dose: 22.8% mean body weight reduction
• 4 mg dose: 17.1% mean body weight reduction
• Placebo: 2.1% mean body weight reduction

Notably, at the 12 mg dose, the weight loss curve had not yet plateaued at 48 weeks — participants were still losing weight when the trial ended, suggesting that longer treatment could produce even greater losses.

The trial also revealed a finding that caught the medical community's attention: participants on retatrutide experienced up to 86% reduction in liver fat. For context, non-alcoholic fatty liver disease (NAFLD) affects roughly 25% of the global adult population, and no medication currently on the market achieves liver fat reduction of that magnitude. This effect is attributed to the glucagon receptor component.

Phase 3 trial — TRIUMPH-4 (2025)

The first Phase 3 results, reported in December 2025, confirmed and extended the Phase 2 findings:

• 28.7% mean body weight loss at the 12 mg dose over 68 weeks
• Participants lost an average of 71.2 lbs (32.3 kg)
• Significant improvements in osteoarthritis-related pain and physical function

This places retatrutide ahead of every existing obesity medication. For comparison, the SURMOUNT-5 head-to-head trial showed tirzepatide producing 47% more weight loss than semaglutide — and retatrutide appears to exceed tirzepatide by a similar margin.

Seven additional Phase 3 trials under the TRIUMPH program are expected to report throughout 2026, evaluating retatrutide for type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes.

Retatrutide vs. semaglutide vs. tirzepatide

The three compounds represent three generations of the same scientific idea — using gut hormones to regulate appetite and metabolism. But they differ in meaningful ways beyond just weight loss numbers.

The glucagon receptor gives retatrutide a metabolic advantage that the other two compounds lack. Semaglutide and tirzepatide primarily work by reducing how much you eat. Retatrutide does that and increases how much energy your body burns at rest — essentially attacking the calorie equation from both sides. This is likely why the appetite cycle patterns people experience on retatrutide tend to feel different from semaglutide or tirzepatide.

However, more receptor activity also means more potential for side effects, which brings us to the safety data.

Retatrutide side effects and safety

Like all GLP-1 class medications, retatrutide's most common side effects are gastrointestinal. But the glucagon receptor adds a few wrinkles that don't appear with semaglutide or tirzepatide.

Common side effects

• Nausea: The most frequent adverse event. In Phase 2, rates ranged from 14% at 1 mg to 60% at 12 mg — a clear dose-dependent pattern. Most nausea occurs during dose escalation and improves over time.
• Diarrhea: Reported across all dose levels, more common at higher doses.
• Vomiting: More frequent than with semaglutide, particularly at the 8 mg and 12 mg doses.
• Constipation: Similar rates to tirzepatide. GLP-1 activity slows gastric motility.
• Decreased appetite: This is technically the intended effect, but at high doses it can become severe enough to cause concern about malnutrition.

The unique finding: dysesthesia

This is the side effect that has no parallel in the semaglutide or tirzepatide literature. In Phase 3, dysesthesia — tingling, numbness, or altered skin sensation — affected approximately 21% of participants at the 12 mg dose. Researchers believe this is linked to the glucagon receptor activity, since glucagon signaling can influence sensory nerve function. The symptoms are generally described as mild and transient, but it's a novel finding that warrants attention as more data emerges.

Heart rate changes

Dose-dependent increases in heart rate were observed, peaking at approximately 4–7 beats per minute above baseline at the 12 mg dose around week 24, with rates declining again by weeks 36 to 48. This is a pattern shared with other GLP-1 medications but appears slightly more pronounced with retatrutide.

Serious adverse events

In Phase 2, serious adverse events occurred at comparable rates in retatrutide and placebo groups — approximately 4% in each. Pancreatitis was reported in roughly 0.4% of participants, and gallbladder issues in about 1.1%. These are known class effects of GLP-1 medications. Discontinuation rates in Phase 3 were 12.2% at 9 mg and 18.2% at 12 mg, compared to 4% with placebo.

For a broader overview of peptide safety principles, our side effects and safety guide covers what applies across all peptide compounds.

Retatrutide dosing: what the clinical trials used

Understanding the dosing protocols used in clinical trials provides important context, though these are investigational doses and not prescribing guidance.

In both Phase 2 and Phase 3 trials, retatrutide was administered as a once-weekly subcutaneous injection with a gradual dose escalation schedule:

• Starting dose: 0.5 mg weekly for the initial escalation period
• Escalation: Doses increased every 4 weeks — typically 0.5 → 1 → 2 → 4 → 8 → 12 mg
• Target doses studied: 1 mg, 4 mg, 8 mg, and 12 mg weekly
• Most effective dose: 12 mg weekly (28.7% weight loss in Phase 3)

The slow escalation is critical. The gradual ramp allows the body to adapt to the GI effects — particularly nausea — that are most intense during the initial weeks. In Phase 2, groups that started at lower doses experienced significantly less nausea than those escalated more quickly.

Retatrutide is typically available as a lyophilized powder in research settings. If you're calculating reconstitution volumes, the math is the same as any peptide: vial size (mg) divided by water volume (mL) gives you concentration per mL. A 20 mg vial reconstituted with 2 mL of bacteriostatic water yields 10 mg/mL, or 100 mcg per unit on a U-100 insulin syringe. Our reconstitution guide covers sterile technique and storage best practices for reconstituted peptides.

Retatrutide and meal planning on a triple agonist

One of the most practical questions people ask about retatrutide is how to eat while taking it. The appetite suppression is intense — more aggressive than semaglutide and comparable to or stronger than tirzepatide, especially during the first 72 hours after injection.

The same weekly appetite cycle that applies to other GLP-1 medications applies here, but the glucagon component adds a nuance: your body is burning more energy even on suppressed appetite days. This means the risk of undereating — and losing lean muscle mass — is amplified compared to semaglutide or tirzepatide.

The critical nutrition priorities:

• Protein is non-negotiable. At least 1.2–1.6g per kg of body weight daily, distributed across 3-4 meals. The glucagon-driven increase in energy expenditure makes muscle preservation harder if protein intake drops.
• Don't skip meals on peak suppression days. Even when food sounds unappealing on days 1-3, hitting minimum calorie targets prevents metabolic downregulation and lean mass catabolism.
• Hydration matters more. Between the GLP-1 slowing gastric emptying and the glucagon increasing metabolic rate, dehydration risk is higher. Aim for at least 64 oz of water daily.

Is retatrutide legal? Availability in 2026

As of April 2026, retatrutide is not approved by the FDA or any other regulatory agency. Eli Lilly has not submitted a New Drug Application. The compound is currently midway through its Phase 3 clinical trial program (TRIUMPH), with seven additional trials expected to report results throughout 2026.

If all trials are successful, an NDA submission is expected in late 2026 or early 2027. Based on typical FDA review timelines, the earliest realistic approval window is 2027–2028.

In the meantime, retatrutide is available through research chemical vendors in the same regulatory gray area as other unapproved peptides. It is sold as a lyophilized powder labeled "for research use only" — the same classification used for compounds like BPC-157 and TB-500. This means:

• It is legal to purchase for research purposes
• It is not legal to sell for human consumption
• Quality control varies significantly between vendors — purity testing, accurate dosing, and contamination risk are real concerns
• The regulatory landscape for peptides is shifting, and enforcement has been increasing

If you're sourcing retatrutide through research channels, every principle in our peptide sourcing guide applies — third-party testing, vendor reputation, and realistic expectations about what you're actually getting.

What retatrutide doesn't tell us yet

For all its impressive data, retatrutide has significant unknowns that deserve honest acknowledgment:

• Long-term safety data doesn't exist yet. The longest trial ran 68 weeks. We don't know what happens with years of continuous use — and with a triple-agonist mechanism, the long-term profile could differ from semaglutide and tirzepatide in unpredictable ways.
• Weight regain after stopping. Semaglutide and tirzepatide studies both show significant weight regain after discontinuation. There's no reason to expect retatrutide will be different, but the data to confirm this hasn't been collected yet.
• Cardiovascular outcomes are pending. While both semaglutide and tirzepatide have shown cardiovascular benefits in dedicated trials, retatrutide's cardiovascular outcome trial is still underway. The glucagon receptor component is particularly important here — glucagon can influence heart rate and lipid metabolism in ways that require dedicated safety evaluation.
• Dysesthesia is poorly understood. The 21% incidence of tingling and altered sensation at the 12 mg dose is novel in this drug class. The mechanism isn't fully characterized, and long-term implications are unknown.
• Interaction with other peptides. Many people in the research peptide community combine retatrutide with other compounds. There is zero clinical data on these combinations. If you're cycling or stacking peptides, you're navigating without a map.

The bottom line

Retatrutide represents a genuine advancement in obesity pharmacology. The triple-agonist mechanism — adding glucagon to the GLP-1 and GIP pathways — produces weight loss numbers that exceed anything previously reported in clinical trials. The liver fat reduction data is particularly notable, given the global prevalence of fatty liver disease.

But "most effective" doesn't mean "best for everyone." Retatrutide is not yet approved by any regulatory agency. Its long-term safety profile is unknown. It produces more intense side effects than its predecessors at equivalent efficacy doses, including the novel dysesthesia finding. And the research chemical versions available through grey market vendors carry all the quality and purity concerns that come with unregulated compounds.

If you're currently on semaglutide or tirzepatide and getting good results, there's no evidence-based reason to switch to an unapproved compound with less safety data. If you're exploring retatrutide through research channels, do so with realistic expectations: the clinical trial results are from pharmaceutical-grade material administered under medical supervision, which is a different context than self-administration of research chemicals.

The science behind retatrutide is compelling. The caution is warranted. Both things can be true.